FDA declines to approve Enzyvant regenerative therapy on manufacturing concernsApproval Rejection, Athymia, FDA, FDA/Regulatory, Manufacturing, Regenerative Therapy, Regenerative TissueThe U.S. Food and Drug Administration declined to approve Enzyvant’s regenerative tissue therapy for a rare immunodeficiency disorder and raised concerns about the privately held drug developer’s manufacturing. Read more December 5, 2019/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2019-12-05 10:46:432019-12-05 10:46:43FDA declines to approve Enzyvant regenerative therapy on manufacturing concerns